Posted on March 27, 2013 by Sitemaster
A German company called CureVac GmbH has started Phase IIb clinical trials of another cancer “vaccine” for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: castration-resistant, CureVac, CV9104, immunotherapy, mCRPC, metastatic, vaccine | 2 Comments »
Posted on March 22, 2013 by Sitemaster
A new article on the Medscape Oncology web site (and again correlated with a media release sent out by the European Association for Urology [EAU] from their annual meeting in Milan, Italy) is headed “Prostate cancer vaccine shows promise.” However, the degree of that “promise” appears to be open to some question. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: castration, dexamethasone, multi-peptide, outcome, PSA, resistant, trial, vaccine | 7 Comments »
Posted on June 12, 2012 by Sitemaster
A research team at the University of Iowa is seeking patients to enroll in Phase II clinical trials of a new form of vaccine immunotherapeutic to treat men with recurrent prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: adenovirus, castration-resistant, recurrent, trial, vaccine | 8 Comments »
Posted on April 9, 2012 by Sitemaster
The idea that we might be able to use a single therapeutic “vaccine” to treat patients with many different types of cancer is not new … and has yet to be substantiated in any large clinical trial. However, … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: ImMucin, therapeutic, vaccine | 2 Comments »
Posted on October 17, 2011 by Sitemaster
In May this year we initially commented on a media announcement about a new form of vaccine-like therapy that was entering Phase III clinical trials for the first-line treatment of intermediate- and high-risk prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: ProstAtak, radiation, Theragene, vaccine | 2 Comments »
Posted on June 20, 2011 by Sitemaster
Now curing prostate cancer in mice absolutely does not necessarily imply that the same vaccine can be used to “cure prostate cancer in man,” … but the technical capability is certainly a step in the right direction (if it really is true). … READ MORE …
Filed under: Drugs in development | Tagged: cure, mouse, vaccine | 5 Comments »
Posted on May 23, 2011 by Sitemaster
A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer. … READ MORE …
Filed under: Drugs in development, Management | Tagged: AdV-tk, gene suicide, immunotherapy, localized, ProstAtak, vaccine, valacyclovir | Leave a Comment »
Posted on April 20, 2011 by Sitemaster
As some readers may be aware, one of the great biologic discoveries of the late 20th Century was the association between the length of the telomere (a piece of repeating DNA at the tips of each chromosome) and the ability of an individual cell to divide and replicate. … READ MORE …
Filed under: Drugs in development | Tagged: Adamis, TeloB-VAX, telomerase, telomere, vaccine | Leave a Comment »
Posted on May 18, 2010 by Sitemaster
Research into new “vaccine” immunotherapies for prostate cancer continues to be a hot topic following the approval of Dendreon’s Provenge just 3 weeks ago. … READ MORE …
Filed under: Drugs in development | Tagged: AE37, immunotherapy, vaccine | Leave a Comment »
Posted on April 19, 2010 by Sitemaster
Straight from a “late-breaking poster” at the annual meeting of the Association for the Advancement of Cancer Research going on in Washington, DC, comes data about BPX-101 — another dendritic cell-based immunotherapeutic “vaccine” for the possible treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: BPX-103, castration-resistant prostate cancer, CRPC, vaccine | 3 Comments »
Posted on April 13, 2010 by Sitemaster
We have heard that another investigational vaccine therapy has started Phase I clinical trials that will include patients with advanced prostate cancer who “have failed at least 1 course of an accepted hormonal therapy.” … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: DPX-0907, trial, vaccine | Leave a Comment »
Posted on January 26, 2010 by Sitemaster
According to a story on ScienceDaily today, investigators are continuing to plan for a Phase III clinical trial of PROSTVAC-VF — a poxvirus-based prostate cancer “vaccine” — in men with castration-resistant prostate cancer (CRPC). … READ MORE …
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, immunobiologics, PROSTVAC-VF, vaccine | 14 Comments »
Posted on December 7, 2009 by Sitemaster
While we are all waiting for the approval of Provenge, it is worth noting that a research group at the University of Iowa has developed a very different type of prostate cancer treatment based on older technology. … READ MORE …
Filed under: Drugs in development | Tagged: adenovirus, PSA, vaccine | 2 Comments »
Posted on November 13, 2009 by Sitemaster
In another front-page article this morning, the New York Times discusses the failure of potential patients and the medical community to take seriously the opportunities actually proven to prevent certain types of cancer. … READ MORE …
Filed under: Prevention | Tagged: Prevention, vaccine | Leave a Comment »
Posted on August 21, 2009 by Sitemaster
In today’s reports we note items related to:
- Whether add-back estrogen improves cognitive function in men on ADT
- Exercise and its impact on the side effects of ADT
- A new technique for delivering prostate cancer “vaccines”
- The potential of VEGF inhibitors in prostate cancer treatment … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapoy, cognitive function, electroporation, estrogen, exercise, vaccine, VEGF inhibitor | Leave a Comment »